Abstract
Proteolytic enzymes have been implicated as the pathological agent in a number of disease states. For this reason proteases are attractive therapeutic targets. Phage display of peptide libraries can be used to identify peptides that may be used either directly as inhibitors or serve as leads in the generation of prodrugs and peptidomimetics.
Keywords: Phage Display, Protease Ligand, peptidomimetics, Plasma kallikrein, chymotrypsin, allosteric mechanism
Current Pharmaceutical Biotechnology
Title: Phage Display as a Tool for Protease Ligand Discovery
Volume: 3 Issue: 1
Author(s): Andrew E. Nixon
Affiliation:
Keywords: Phage Display, Protease Ligand, peptidomimetics, Plasma kallikrein, chymotrypsin, allosteric mechanism
Abstract: Proteolytic enzymes have been implicated as the pathological agent in a number of disease states. For this reason proteases are attractive therapeutic targets. Phage display of peptide libraries can be used to identify peptides that may be used either directly as inhibitors or serve as leads in the generation of prodrugs and peptidomimetics.
Export Options
About this article
Cite this article as:
Nixon E. Andrew, Phage Display as a Tool for Protease Ligand Discovery, Current Pharmaceutical Biotechnology 2002; 3 (1) . https://dx.doi.org/10.2174/1389201023378526
DOI https://dx.doi.org/10.2174/1389201023378526 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Minority Aging Research Study: Ongoing Efforts to Obtain Brain Donation in African Americans without Dementia
Current Alzheimer Research Pharmacovigilance and the Cardiovascular System: Two Sides to Every Story
Current Drug Safety Notch Inhibitors as a New Tool in the War on Cancer: A Pathway to Watch
Current Pharmaceutical Biotechnology Recent Advances in the Discovery of α1-Adrenoceptor Agonists
Current Topics in Medicinal Chemistry Repurposing Drugs for Cancer Prevention
Current Topics in Medicinal Chemistry Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine Gene Therapy in Lung Transplantation
Current Gene Therapy Blood Pressure and the Risk of Dementia: A Dose-Response Meta-Analysis of Prospective Studies
Current Neurovascular Research PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism
Current Drug Targets T-type Ca Channel Blockers in Patients with Chronic Kidney Disease in Clinical Practice
Current Hypertension Reviews Iron Chelating Strategies in Systemic Metal Overload, Neurodegeneration and Cancer
Current Medicinal Chemistry Regulation of HIPK Proteins by MicroRNAs
MicroRNA Editorial (Thematic Issue: Experimental Pharmacological Targets for the Treatment of Cardiac Arrhythmias: Beyond the Vaughn-Williams Classification)
Current Medicinal Chemistry Diabetes, the Renin-Angiotensin System and Heart Disease
Current Vascular Pharmacology Cellular and Molecular Mechanisms of Diuretic Plants: An Overview
Current Pharmaceutical Design Medications not Intended for Treatment of Dyslipidemias and with a Variable Effect on Lipids
Current Pharmaceutical Design Supplementation of Creatine and Ribose Prevents Apoptosis and Right Ventricle Hypertrophy in Hypoxic Hearts
Current Pharmaceutical Design Pulmonary Hypertension and Lung Transplantation
Current Hypertension Reviews Astrocytes: Targets for Neuroprotection in Stroke
Central Nervous System Agents in Medicinal Chemistry The ACE2-Ang-(1-7)-Mas Axis and Cardioprotection
Current Cardiology Reviews